Prime MedicinePRME +8.03%25 PS Ratio is 127.04 as of Jun. 27, 2026, which is 6% above its 10-year median of 119.39. GuruFocus rates PRME with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 936 Biotechnology companies, Prime Medicine ranks worse than 86.75% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Prime Medicine's share price is $3.43.
Prime Medicine's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.03. Hence, Prime Medicine's PS Ratio for today is 127.04.
Warning Sign:
Prime Medicine Inc stock PS Ratio (=127.04) is close to 1-year high of 141.11.
The historical rank and industry rank for Prime Medicine's PS Ratio or its related term are showing as below:
PRME'
s PS Ratio Range Over the Past 10 Years
Min: 39.33 Med: 119.39 Max: 1185
Current: 127.04
During the past 6 years, Prime Medicine's highest PS Ratio was 1185.00. The lowest was 39.33. And the median was 119.39.
PRME's PS Ratio is ranked worse than 86.75% of 936
companies
in the Biotechnology industry
Industry Median: 9.165
vs PRME: 127.04
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Prime Medicine PS Ratio Related Terms
Prime Medicine PS Ratio Historical Data
* Premium members only.
The historical data trend for Prime Medicine's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Prime Medicine's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prime Medicine PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Prime Medicine's PS Ratio distribution charts can be found below:
* The bar in red indicates where Prime Medicine's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Prime Medicine's Share Price of today is $3.43. Prime Medicine's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Prime Medicine (PRME) has a PS Ratio of 127.04 as of Jun. 27, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Prime Medicine and its competitors. This is near median its historical median of 119.39. Over the past decade, Prime Medicine's PS Ratio has ranged from 39.33 to 1,185.00. According to the industry distribution chart, Prime Medicine ranks #812 out of 936 companies in the Biotechnology industry, placing it in the top 86.8%.
Is Prime Medicine's PS Ratio too high?
Prime Medicine's current PS Ratio of 127.04 is near median its 10-year median of 119.39. Over the past 10 years, this metric has ranged from a low of 39.33 to a high of 1,185.00. The Biotechnology industry median PS Ratio is 9.17. Prime Medicine's value of 127.04 is 1286.1% above this industry median. Based on the distribution chart, Prime Medicine ranks #812 out of 936 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Prime Medicine has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prime Medicine's PS Ratio compare to IMMX and SGP?
According to the Biotechnology industry distribution chart, Prime Medicine ranks #812 out of 936 companies for PS Ratio. This places Prime Medicine in the lower half of its industry. The industry median PS Ratio is 9.17. Prime Medicine's value of 127.04 is 1286.1% above this benchmark. Historically, Prime Medicine's own PS Ratio has ranged from 39.33 to 1,185.00 over the past decade. While the company's 10-year median is 119.39 vs. the industry median of 9.17, Prime Medicine has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.17, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prime Medicine's current PS Ratio of 127.04 is 1286.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Prime Medicine and its competitors. For the Biotechnology industry, the median PS Ratio is 9.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prime Medicine's current PS Ratio is 127.04, which is near median its own 10-year median of 119.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prime Medicine stock overvalued right now?
Prime Medicine (PRME) has a current PS Ratio of 127.04. The current PS Ratio is 127.04, which is near median its 10-year median of 119.39 and 1286.1% above the Biotechnology industry median of 9.17. Prime Medicine's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Prime Medicine (PRME), the current PS Ratio is 127.04 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.
25GF Score
Get the complete analysis for PRME
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRME has been successfully added to your 
